Drugs / recombinant tissue-type plasminogen activator
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03927508 | Mar → Dec 2019 | pulmonary embolism | Thrombolex, Inc. | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | recombinant tissue-type plasminogen activator | “The total dose of r-tPA (recombinant tissue-type plasminogen activator) was 14 mgs in bilateral PE and 12 mgs in unilateral PE over 8 hours delivered via the expanded BEC.” PMID 33356383 ↗ Dec 2020 |
| Known as | r-tPA | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03927508 ↗ |
| Modality | Protein / enzyme biologic | “The total dose of r-tPA (recombinant tissue-type plasminogen activator) was 14 mgs in bilateral PE and 12 mgs in unilateral PE over 8 hours delivered via the expanded BEC.” PMID 33356383 ↗ Dec 2020 |
| Route | Other | “localized infusion of therapeutic agents into the pulmonary artery” NCT03927508 ↗ |